PYC achieves key designation for drug aiming to treat blinding eye disease ADOA
PYC Therapeutics Ltd has received a special designation from the FDA for its drug PYC-001 to treat a childhood-originating eye disease.
The Watchlist
Previous Video
Next Video
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online